Views: 0 Author: Site Editor Publish Time: 2025-12-05 Origin: Site
• Cannabis interacts with the endocannabinoid system (ECS), producing both therapeutic effects in targeted conditions and measurable risks—especially with chronic, early-onset, or high-dose use.
• Potential Medical Benefits of Cannabis; Cannabis-Induced Appetite Stimulation; Long-Term Cannabis–Weight Relationship; Endocannabinoids as Physiological Signals; CB2 Receptors in Immune Regulation.
• Endogenous ligands (anandamide, 2‑AG), metabolic enzymes, and receptors CB1 and CB2.
• Homeostatic regulation: mood, memory, pain, appetite, metabolism, sleep, immune response, and stress adaptation.
• THC: primary psychoactive component; CB1 agonist in CNS.
• CBD: non-intoxicating; modulates ECS indirectly and has complex pharmacology.
• Exogenous cannabinoids can enhance, mimic, or disrupt endogenous signaling, altering appetite, mood, pain perception, and immune responses.
• Evidence supports benefit for chronic neuropathic pain and MS-related spasticity as adjunctive therapies.
• Oral cannabinoids and dronabinol can reduce chemotherapy-induced nausea and stimulate appetite in wasting conditions (HIV/AIDS, cancer cachexia).
• Pharmaceutical CBD (e.g., Epidiolex) is approved for certain treatment-resistant epilepsies.
• CB2 receptor modulation shows potential for inflammatory and autoimmune conditions; clinical translation remains preliminary.
• THC increases snack intake and food reward by acting on CB1 receptors in hypothalamic and limbic circuits.
• In patients with wasting conditions, cannabinoids increase caloric intake and may support modest weight gain; evidence varies by study and sample size.
• Large cohort studies often report lower average BMI among regular cannabis users despite higher reported caloric intake in some subgroups.
• Acute vs chronic effects; co-use of substances; reward competition; metabolic regulatory hypotheses.
• Rodent models show differential weight trajectories depending on baseline weight and dosing, supporting a non-linear relationship.
• Endocannabinoids are produced and degraded rapidly to fine-tune synaptic and systemic activity.
• ECS contributes to exercise-induced mood elevation (runner’s high) and regulates stress responses and social reward.
• CB2 is primarily expressed in immune cells; activation modulates cytokine release, inflammation, and immune cell migration.
• Interest in CB2-targeted therapies for inflammatory disorders persists, but clinical evidence is limited.
• Acute cognitive impairment, anxiety/paranoia, tachycardia, and impaired psychomotor function.
• Dependence, cognitive effects (notably with adolescent onset), respiratory harms from smoking, and psychiatric exacerbation in susceptible individuals.
• Adolescents, pregnant/breastfeeding individuals, those with psychosis family history, and cardiovascular disease patients require caution.
• Pharmaceutical-grade cannabinoids differ from unregulated products in potency, purity, and evidence base.
• Rimonabant showed weight-loss efficacy but caused severe psychiatric adverse events, underscoring ECS complexity.
• Use indication-specific, standardized formulations under medical supervision when possible.
• Consider cannabinoids only after standard therapies fail or as informed adjuncts.
• Monitor psychiatric and cardiovascular signs; prefer non-smoking routes; counsel on dependence risks.
• Not consistently—acute appetite increases are documented, but long-term population studies show mixed or inverse associations; individual outcomes vary.
• No—ECS endocannabinoids modulate mood and can contribute to exercise-induced euphoria, but endogenous signaling differs from THC exposure.
• Certain cannabinoids have evidence as adjunctive therapy for neuropathic pain; benefits should be weighed against risks.
